YTHDF2 and hepatocellular carcinoma: The study revealed that YTHDF2 inhibits HCC progression through m6A modification by decreasing the stability of interleukin 11 (IL11) and serpin family E member 2 (SERPINE2) mRNA, which are involved in tumor angiogenesis and inflammation activation respectively (Figure 2A).